Page last updated: 2024-12-07

chlorethylclonidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chlorethylclonidine: RN refers to 2-chloroethyl derivative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104973
CHEMBL ID326967
SCHEMBL ID4107963
SCHEMBL ID18154646
MeSH IDM0147104

Synonyms (29)

Synonym
3x825o680h ,
1h-imidazol-2-amine, n-(2,6-dichlorophenyl)-4,5-dihydro-, mono(2-chloroethyl) deriv.
unii-3x825o680h
1h-imidazol-2-amino, n-(2,6-dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-
77472-95-8
lopac-b-003
NCGC00015117-01
PDSP1_000070
PDSP2_000070
LOPAC0_000195
NCGC00162088-02
1h-imidazol-2-amine, n-(2,6-dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-
chloroethylclonidine
n-(2,6-dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-1h-imidazol-2-amine
chlorethylclonidine
NCGC00162088-01
NCGC00015117-04
L000181
CHEMBL326967
n-[2,6-dichloro-4-[[2-chloroethyl(methyl)amino]methyl]phenyl]-4,5-dihydro-1h-imidazol-2-amine
CCG-204290
NCGC00015117-03
NCGC00015117-02
nc-17
SCHEMBL4107963
SCHEMBL18154646
DTXSID40913463
Q5103062
SDCCGSBI-0050183.P002

Research Excerpts

Effects

ExcerptReferenceRelevance
"Chlorethylclonidine (CEC) has previously been shown to inactivate only a subpopulation of the alpha 1-adrenergic receptor binding sites in rat brain. "( Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine.
Abel, PW; Han, C; Minneman, KP, 1987
)
1.96

Treatment

Chlorethylclonidine treatment had no significant effect on resting systemic arterial blood pressure or heart rate and shifted the phenylephrine pressor dose-response curve only 2.4-fold to the right. Treatment with chlo did not alter the noradrenaline contractions in the vas deferens.

ExcerptReferenceRelevance
"5. Chlorethylclonidine (CEC) treatment nearly abolished (-)noradrenaline (NA) (10 microM)-induced inositol[1,4,5]trisphosphate (IP3) production, and BMY-7378 inhibited the response with a Ki value of 0.3 nM, which value was similar to that obtained in the cells expressing alpha 1D-AR."( Characterization of alpha 1-adrenoceptors expressed in a novel vascular smooth muscle cell line cloned from p53 knockout mice, P53LMAC01 (AC01) cells.
Goda, N; Nakayama, Y; Ohmi, K; Shinoura, H; Tsujimoto, G, 1999
)
0.82
"Chlorethylclonidine treatment had no significant effect on resting systemic arterial blood pressure or heart rate and shifted the phenylephrine pressor dose-response curve only 2.4-fold to the right."( The role of alpha 1-adrenoceptor subtypes in the regulation of arterial blood pressure.
Butler, BT; Piascik, MT; Pruitt, TA, 1990
)
1
"Pretreatment with chlorethylclonidine (10(-4) M for 30 min) did not alter the noradrenaline contractions in the vas deferens, but contractions to noradrenaline and phenylephrine in the spleen were shifted 30 and 300 fold to the right of the control curve, respectively."( Evidence for a functional alpha 1A- (alpha 1C-) adrenoceptor mediating contraction of the rat epididymal vas deferens and an alpha 1B-adrenoceptor mediating contraction of the rat spleen.
Burt, RP; Chapple, CR; Marshall, I, 1995
)
0.61
"Pretreatment with chlorethylclonidine (CEC) at concentrations ranging from 0.1 microM to 100 microM attenuated the maximum contraction to phenylephrine in a concentration-dependent manner in both the urethra and artery."( Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.
Hatano, A; Koizumi, T; Komeyama, T; Takahashi, H; Takeda, M; Tamaki, M, 1994
)
0.61
"Pretreatment with chlorethylclonidine (CEC) at concentrations higher than 1 microM inhibited 700 pM [3H]-prazosin binding to the prostatic portion by approximately 50%."( Identification of alpha 1-adrenoceptor subtypes in the rat vas deferens: binding and functional studies.
Kigoshi, S; Muramatsu, I; Ohmura, T; Oshita, M, 1992
)
0.61
"Pretreatment with chlorethylclonidine (CEC) slightly attenuated only the contractions induced by low concentrations of noradrenaline."( Relation between adrenergic neurogenic contraction and alpha 1-adrenoceptor subtypes in dog mesenteric and carotid arteries and rabbit carotid arteries.
Muramatsu, I, 1991
)
0.6
"Treatment with chlorethylclonidine inhibited 70-80% of the stimulation of labeling induced by epinephrine in rat liver, but only 30-40% of that in aorta."( Alpha 1-adrenoceptor subtypes in aorta (alpha 1A) and liver (alpha 1B).
García-Sáinz, JA; Torres-Márquez, ME; Villalobos-Molina, R, 1991
)
0.62
"Pretreatment with chlorethylclonidine (CEC; 10 mumols/l), which inactivates only alpha 1b receptors, caused 98.8% and 97.0% decreases in the density of specific [3H]prazosin-binding sites in 5H and 6H cells respectively."( Characterization of alpha 1-adrenergic receptor subtypes linked to iodide efflux in rat FRTL cells.
Endo, T; Hashimoto, K; Onaya, T; Shimura, H; Tsujimoto, G; Watanabe, K, 1990
)
0.6
"Treatment with chlorethylclonidine dose dependently suppressed 125I-BE binding sites and norepinephrine-induced phosphorylase activation in rat hepatocytes, whereas in rabbit aorta it resulted in only a 31% decrease in 125I-BE binding sites, with little effect on phosphorylase activation."( Glycogen phosphorylase activation by two different alpha 1-adrenergic receptor subtypes: methoxamine selectively stimulates a putative alpha 1-adrenergic receptor subtype (alpha 1a) that couples with Ca2+ influx.
Hashimoto, K; Suzuki, E; Tsujimoto, A; Tsujimoto, G, 1989
)
0.62

Dosage Studied

ExcerptRelevanceReference
" CEC treatment had little effect on the pressor dose-response curve of either phenylephrine or BHT 920."( Effect of chlorethylclonidine on arterial blood pressure and heart rate in the conscious rat.
Piascik, MT; Pruitt, TA; Sparks, MS, 1992
)
0.69
" On the other hand, in monkey lingual arteries, diltiazem failed to depress the NE-induced dose-response curve, and the response was attenuated only about 60% in Ca(2+)-free solution."( Pharmacological properties of alpha 1-adrenoceptor-mediated vasoconstrictions in dog and monkey lingual arteries: evidence for subtypes of alpha 1-adrenoceptors.
Chiba, S; Skrbic, R, 1992
)
0.28
" In control aortic rings the dose-response curves for either clonidine or naphazoline were biphasic, consisting of high- and low-affinity components."( Interaction of imidazolines with alkylation-sensitive and -resistant alpha-1 adrenoceptor subtypes.
Piascik, MT; Pruitt, TA; Sparks, MS, 1991
)
0.28
"1-10 nM) shifted the dose-response curves for norepinephrine and phenylephrine to the right."( Agonist interaction with alkylation-sensitive and -resistant alpha-1 adrenoceptor subtypes.
Butler, BT; Kusiak, JW; Piascik, MT; Pruitt, TA, 1990
)
0.28
" Chloroethylclonidine (1-5 X 10(-5) M) shifted noradrenaline dose-response curve to the right approximately 5000-fold without depressing the maximum."( Chloroethylclonidine unmasks a non-alpha-adrenoceptor noradrenaline binding site in the rat aorta.
Bevan, JA; Oriowo, MA, 1990
)
0.28
" The dose-response relationship for norepinephrine-induced [Ca2+]i response showed an increase in maximum effect with no change in agonist potency, and the increase in maximum effect was disproportionate to the difference in receptor density."( Effect of receptor density on the receptor-effector coupling: use of cloned and stably expressed alpha 1B-adrenoceptors in CHO cells.
Horie, K; Tsujimoto, G, 1995
)
0.29
" Concentration- or dose-response curves for norepinephrine were obtained from aortic rings, superior mesenteric artery rings or the isolated perfused mesenteric vasculature from male Sprague-Dawley rats."( Functional distribution and role of alpha-1 adrenoceptor subtypes in the mesenteric vasculature of the rat.
Fleming, WW; Kong, JQ; Taylor, DA, 1994
)
0.29
" In the isolated tissue, pretreatment with CEC (10(-5) M, 10 and 30 min) time-dependently shifted to the right the dose-response curve for phenylephrine and decreased the maximal contraction of aortas induced by phenylephrine, but did not shift or decrease those of prostates."( Alpha 1-adrenoceptor subtype in the rat prostate is preferentially the alpha 1A type.
Honda, K; Yazawa, H, 1993
)
0.29
" The dose-response curve for phenylephrine-induced increases in mesenteric or hindlimb vascular resistance was shifted only 2- to 10-fold to the right by CEC."( The regulation of regional hemodynamics by alpha-1 adrenoceptor subtypes in the conscious rat.
Barron, KW; Piascik, MT; Smith, MS; Soltis, EE, 1993
)
0.29
"1 mg kg(-1), displaced the dose-response curve approximately six-fold to the right."( Postjunctional alpha1-adrenoceptors in the vasculature of the pithed mouse are of the alpha1A-subtype.
Ibarra, M; López-Guerrero, JJ; Villalobos-Molina, R, 2005
)
0.33
" Dose-response curves for the alpha1-adrenoceptor agonist phenylephrine were generated in the absence and presence of fentanyl."( Fentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery contraction.
Ding, X; McCune, DF; Murray, PA; Perez, DM; Sohn, JT, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency25.25520.100020.879379.4328AID488773; AID588453
NFKB1 protein, partialHomo sapiens (human)Potency11.22020.02827.055915.8489AID895; AID928
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency44.66840.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency15.84890.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926
67.9K proteinVaccinia virusPotency25.28550.00018.4406100.0000AID720579; AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency9.46620.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID488953
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency12.67280.00106.000935.4813AID943; AID944
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency15.10140.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID35146Overall binding displacement in tissues containing only the Alpha-1B adrenergic receptor(rat spleen, rat liver); +1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
AID36771Overall binding displacement in tissues containing only the Alpha-1A adrenergic receptor from rat submaxillary gland1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (288)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (2.08)18.7374
1990's217 (75.35)18.2507
2000's52 (18.06)29.6817
2010's9 (3.13)24.3611
2020's4 (1.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.75 (24.57)
Research Supply Index5.69 (2.92)
Research Growth Index6.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.02%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other291 (98.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]